• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/5/21 6:03:56 AM ET
    $NNOX
    Medical Electronics
    Health Care
    Get the next $NNOX alert in real time by email
    SC 13G 1 r34212sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

    Nano-X Imaging Ltd.
    (Name of Issuer)
     
    Ordinary shares
    (Title of Class of Securities)

     

      M70700105  
      (CUSIP Number)  
     
    December 31, 2020
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 5 pages 
     

     

    CUSIP No.  M70700105
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    YOZMA GROUP KOREA Co., Ltd.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Korea

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    2,512,000

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    2,512,000

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,512,000 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.42%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    (1) Consists of 887,000 ordinary shares held by Yozma Global AI Fund No.2 (“Yozma Fund No.2”), (b) 1,625,000 ordinary shares held by Yozma Global AI Fund No.3 (“Yozma Fund No.3”). Yozma Group Korea is the general partner of each of Yozma Fund No.2 and Yozma Fund No.3. Wonjae Lee is the Chief Executive Officer and controlling shareholder of Yozma Group Korea and is deemed to have voting and dispositive power over the shares held by Yozma Fund No.2 and Yozma Fund No.3

     

     Page 2 of 5 pages 
     

     

    Item 1(a). Name of Issuer:
       
       NANO-X IMAGING LTD (the "Issuer")
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       COMMUNICATIONS CENTER, NEVE ILAN, ISRAEL 9085000
       
    Item 2(a). Name of Person Filing:
       
       YOZMA GROUP KOREA Co., Ltd.
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       7F Building #2, 20, Pangyo-ro 289beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
       
    Item 2(c). Citizenship:
       
       Republic of Korea
       
    Item 2(d). Title of Class of Securities:
       
       Ordinary shares
       
    Item 2(e). CUSIP Number:  M70700105
       
    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable.

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
                      (a) Amount Beneficially Owned: See Item 9 of the cover page.
       (b) Percent of Class: See Item 11 of the cover page.
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: See Item 5 of the cover page.
          (ii) shared power to vote or to direct the vote: See Item 6 of the cover page.
          (iii) sole power to dispose or to direct the disposition of: See Item 7 of the cover page.
          (iv) shared power to dispose or to direct the disposition of: See Item 8 of the cover page.

     

     Page 3 of 5 pages 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       Not applicable.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

     Page 4 of 5 pages 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      March 05, 2021  
      Date  
         
      /s/ Wonjae Lee  
      Signature  
         
      Wonjae Lee, CEO  
      Name/Title  

     

     

    Page 5 of 5 pages

     

     

    Get the next $NNOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NNOX

    DatePrice TargetRatingAnalyst
    1/6/2025$23.00Buy
    D. Boral Capital
    9/8/2023$14.50Buy
    Alliance Global Partners
    1/5/2023$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Daniel Ran bought $3,650 worth of Ordinary shares (1,000 units at $3.65), increasing direct ownership by 17% to 6,950 units (SEC Form 4)

    4 - Nano-X Imaging Ltd. (0001795251) (Issuer)

    9/5/25 5:41:26 PM ET
    $NNOX
    Medical Electronics
    Health Care

    New insider Daniel Ran claimed ownership of 5,950 units of Ordinary Shares (SEC Form 3)

    3 - Nano-X Imaging Ltd. (0001795251) (Issuer)

    9/5/25 2:11:14 PM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Nano-X Imaging with a new price target

    D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00

    1/6/25 9:02:00 AM ET
    $NNOX
    Medical Electronics
    Health Care

    Alliance Global Partners initiated coverage on Nano-X Imaging with a new price target

    Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50

    9/8/23 9:14:06 AM ET
    $NNOX
    Medical Electronics
    Health Care

    Cantor Fitzgerald initiated coverage on Nano-X Imaging with a new price target

    Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00

    1/5/23 7:46:34 AM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Daniel Ran bought $3,650 worth of Ordinary shares (1,000 units at $3.65), increasing direct ownership by 17% to 6,950 units (SEC Form 4)

    4 - Nano-X Imaging Ltd. (0001795251) (Issuer)

    9/5/25 5:41:26 PM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging

    Collaboration spans workers' compensation, nursing homes, and outpatient clinics PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced a collaboration between its U.S. subsidiary Nanox Impact Inc. and Monarch Medical Management and Billing LLC ("Monarch"), an experienced healthcare management organization with established relationships across industry sectors, to deploy Nanox's advanced imaging solutions across multiple healthcare segments including workers' compensation, nursing home facilities, and outpatient clinics. As part of the collaboration, Nan

    9/18/25 8:00:07 AM ET
    $NNOX
    Medical Electronics
    Health Care

    Nanox Announces Second Quarter of 2025 Financial Results and Provides Business Update

    Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024.Grew Nanox.ARC system sales funnel exponentially in the quarter.The Company notified the FD

    8/12/25 8:00:00 AM ET
    $NNOX
    Medical Electronics
    Health Care

    Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025

    PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2025, before market open on Tuesday, August 12, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q2 2025 Conference Call. The live webcast of the conference call may be accessed by

    8/1/25 4:05:00 PM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    SEC Filings

    View All

    SEC Form 6-K filed by NANO-X IMAGING LTD

    6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

    8/12/25 8:05:17 AM ET
    $NNOX
    Medical Electronics
    Health Care

    SEC Form 6-K filed by NANO-X IMAGING LTD

    6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

    5/22/25 8:05:17 AM ET
    $NNOX
    Medical Electronics
    Health Care

    SEC Form 6-K filed by NANO-X IMAGING LTD

    6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

    4/17/25 8:40:02 AM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Financials

    Live finance-specific insights

    View All

    Nanox Announces Second Quarter of 2025 Financial Results and Provides Business Update

    Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024.Grew Nanox.ARC system sales funnel exponentially in the quarter.The Company notified the FD

    8/12/25 8:00:00 AM ET
    $NNOX
    Medical Electronics
    Health Care

    Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025

    PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2025, before market open on Tuesday, August 12, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q2 2025 Conference Call. The live webcast of the conference call may be accessed by

    8/1/25 4:05:00 PM ET
    $NNOX
    Medical Electronics
    Health Care

    Nanox Announces First Quarter 2025 Financial Results and Provides Business Updates

    PETACH TIKVA, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2025, and provided a business update. Recent Highlights: Generated $2.8 million in revenue in the first quarter of 2025, compared to $2.6 million in the first quarter of 2024.Received 510(k) clearance from the FDA for the Nanox.ARC X, its updated multi-source digital Tomosynthesis system.Signed multiple commercial agreements to market the Nanox.ARC and the Nanox.AI solutions. "Since the beginning of 2025, Nanox has made consistent progress marketing our full end-

    5/22/25 8:00:00 AM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Leadership Updates

    Live Leadership Updates

    View All

    Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

    NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we

    5/3/21 8:00:00 AM ET
    $NNOX
    Medical Electronics
    Health Care

    $NNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

    SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

    3/7/24 12:29:51 PM ET
    $NNOX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by NANO-X IMAGING LTD

    SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)

    2/6/24 9:36:34 AM ET
    $NNOX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

    SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

    2/14/23 4:15:16 PM ET
    $NNOX
    Medical Electronics
    Health Care